Twitter | Search | |
Search Refresh
Virginia E. Kelsen 3h
When a graduate is training other adults to use valuable engineering skills before she turns 25.... 🎓💪🏼🏆 Millions of Californians’ jobs could be affected by automation — a scenario the next governor has to address
Reply Retweet Like
Anne-Pierre Pickaert 24h
thanks Dr Marie Robin for her overview of in-vivo depletion in patients. RCTs comparing & matched unrelated transplants, both arms being administered cyclophosphamide after transplant, look promising.
Reply Retweet Like
Bruce Levine Oct 5
A great day at building a great team for therapies
Reply Retweet Like
Parker Institute Oct 13
What’s comes after CAR cancer ? Cell therapy for : . PICI's Jeff Bluestone makes the case for regulatory Tcells (Tregs) as the next step in cell therapy . New in
Reply Retweet Like
LosOsosAVID Oct 5
College research & presentations in Mrs. Rivera’s AVID class!!
Reply Retweet Like
Mate Manczinger Oct 12
Combined checkpoint blockade therapy as a neoadjuvant in melanoma. 73% of grade 3 adverse events is thought-provoking. checkpoint blockade in high-risk resectable
Reply Retweet Like
Marilyn Heine Oct 11
The Medicine, Miracles & Masterminds Behind CAR T-Cell Therapy.
Reply Retweet Like
ACIR.org Oct 12
Spotlight: (Original article appears in Cancer Immunology Research )
Reply Retweet Like
PCT Oct 12
Check out this article our experts published in covering the viability of scalable expansion in stirred-tank bioreactors.
Reply Retweet Like
Euro Cancer 2019 Oct 11
Reply Retweet Like
BioPharmaDevice Oct 13
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
Reply Retweet Like
Darcy Salvadore Oct 14
Reply Retweet Like
Teknik_Analiz_Araçları Oct 14
Replying to @Teknik_Analiz_T
Reply Retweet Like
Gayathri Vijayakumar Oct 12
" - essential players in driving and pathogenic responses in ; B cell–depleting therapies have striking efficacy" Fascinating how our very own is a double-edged sword!
Reply Retweet Like
Wyss Institute Oct 12
"We are excited about the potential of this system to tune and generate products with precision that is currently not possible. Clinically, it could result in safer and more potent T cell therapies for patients who need them." -
Reply Retweet Like
Beacon Intelligence Oct 12
The University of Texas MD Anderson Cancer Center reported that allogeneic can provide "borrowed" immunity against virus in progressive multifocal . Find out more at:
Reply Retweet Like
The Bergthaler Lab Oct 11
Breakfast with Nobel Laureate Rolf Zinkernagel (), , and . How to falsify your own hypotheses and break up dogmas. -AB
Reply Retweet Like
LifeSci PR Oct 11
. was featured in about its peer reviewed study in for its drug candidate FR104 and its impact on activation in a preclinical non-human primate model of graft-versus-host disease
Reply Retweet Like
ACIR.org Oct 11
Spotlight: (Original article appears in Immunology & Cell Biology )
Reply Retweet Like
Ken Nitz Oct 10
REALLY??? Cancer patients with rare deadly brain infection treated successfully with off-the-shelf adoptive T-cell therapy ,
Reply Retweet Like